RAPH: Raphael Pharmaceutical Inc. Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 32.19
Enterprise Value ($M) 32.21
Book Value ($M) -0.74
Book Value / Share -0.04
Price / Book -43.38
NCAV ($M) -0.74
NCAV / Share -0.04
Price / NCAV -43.26

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -4.30
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.03
Current Ratio 0.03

Balance Sheet (mrq) ($M)
Current Assets 0.03
Assets 0.03
Liabilities 0.77
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -1.51
Net Income -1.52
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.53
Cash from Investing 0.00
Cash from Financing 0.32

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-31 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REP
2024-08-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT P
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT

(click for more detail)

Similar Companies
PYRGF – PyroGenesis Inc. QBIO – Q BioMed Inc.
QNNTF – Quantum Genomics Société Anonyme RASP – Actavia Life Sciences, Inc.
RBSH – Rebus Holdings, Inc.


Financial data and stock pages provided by
Fintel.io